Search Results

You are looking at 1 - 5 of 5 items for :

  • "idarucizumab" x
  • Medical and Health Sciences x
  • All content x
Clear All
Orvosi Hetilap
Authors: Lajos Driesz, Éva Barabás, Ildikó Bodócs, Zoltán Szántó, György Herr, Gábor Bencsik, László Pál, and József Borbola

Pollack, C. V. Jr., Reilly, P. A., Eikelboom, J., et al.: Idarucizumab for dabigatran reversal. N. Engl. J. Med., 2015, 373 (6), 511–520. 12 Eikelboom, J. W

Restricted access

Glund, S., Stangier, J., Schmohl, M., et al.: Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised

Restricted access

of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc. Health Risk Manag., 2016, 12, 35–44. 10 Pollack, C. V. Jr

Restricted access

anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice. [Teendők súlyos vérzés vagy sürgős sebészeti

Restricted access

anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–1393. 18 Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for

Open access